Published in Cancer Weekly, July 7th, 1997
Under the collaboration, a Phase I/II pilot study is initiated to assess the safety and potential effectiveness of treating malignant melanoma patients with tumor-specific cytotoxic T cells (CTL) produced from patient T cells and activated with peptide epitopes outside the body.
Under the agreement, Cytel provides melanoma-specific, CTL-stimulatory epitope peptides. Baxter provides cell separation systems and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.